Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Effect of Ibuprofen on Skeletal Muscle of Dysferlin-Null Mice.

Collier AF, Gumerson J, Lehtimäki K, Puoliväli J, Jones JW, Kane MA, Manne S, O'Neill A, Windish HP, Ahtoniemi T, Williams BA, Albrecht DE, Bloch RJ.

J Pharmacol Exp Ther. 2018 Mar;364(3):409-419. doi: 10.1124/jpet.117.244244. Epub 2017 Dec 28.

2.

Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for Dysferlinopathy.

Potter RA, Griffin DA, Sondergaard PC, Johnson RW, Pozsgai ER, Heller KN, Peterson EL, Lehtimäki KK, Windish HP, Mittal PJ, Albrecht DE, Mendell JR, Rodino-Klapac LR.

Hum Gene Ther. 2018 Jul;29(7):749-762. doi: 10.1089/hum.2017.062. Epub 2017 Jul 13.

3.

Interferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of Tuberculosis.

Orr MT, Windish HP, Beebe EA, Argilla D, Huang PW, Reese VA, Reed SG, Coler RN.

J Infect Dis. 2015 Aug 1;212(3):495-504. doi: 10.1093/infdis/jiv055. Epub 2015 Jan 30.

4.

6th Dysferlin Conference, 3-6 April 2013, Arlington, Virginia, USA.

Albrecht DE, Rufibach LE, Williams BA, Lee ER, Windish HP, Hwang EY, Shira SR, Mittal P.

Neuromuscul Disord. 2014 Mar;24(3):277-87. doi: 10.1016/j.nmd.2013.11.008. Epub 2013 Nov 23.

PMID:
24480524
5.

MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant.

Orr MT, Duthie MS, Windish HP, Lucas EA, Guderian JA, Hudson TE, Shaverdian N, O'Donnell J, Desbien AL, Reed SG, Coler RN.

Eur J Immunol. 2013 Sep;43(9):2398-408. doi: 10.1002/eji.201243124. Epub 2013 Jul 3.

6.

Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment.

Coler RN, Bertholet S, Pine SO, Orr MT, Reese V, Windish HP, Davis C, Kahn M, Baldwin SL, Reed SG.

J Infect Dis. 2013 Apr 15;207(8):1242-52. doi: 10.1093/infdis/jis425. Epub 2012 Aug 13.

7.

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.

Arias MA, Van Roey GA, Tregoning JS, Moutaftsi M, Coler RN, Windish HP, Reed SG, Carter D, Shattock RJ.

PLoS One. 2012;7(7):e41144. doi: 10.1371/journal.pone.0041144. Epub 2012 Jul 19.

8.

Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate.

Windish HP, Duthie MS, Misquith A, Ireton G, Lucas E, Laurance JD, Bailor RH, Coler RN, Reed SG.

Vaccine. 2011 Oct 13;29(44):7842-8. doi: 10.1016/j.vaccine.2011.07.094. Epub 2011 Aug 2. Erratum in: Vaccine. 2012 Dec 17;31(1):278. Misquith, Ayesha [added].

9.

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.

Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL, Laughlin EM, Duthie MS, Fox CB, Carter D, Friede M, Vedvick TS, Reed SG.

PLoS One. 2011 Jan 26;6(1):e16333. doi: 10.1371/journal.pone.0016333.

10.

Use of defined TLR ligands as adjuvants within human vaccines.

Duthie MS, Windish HP, Fox CB, Reed SG.

Immunol Rev. 2011 Jan;239(1):178-96. doi: 10.1111/j.1600-065X.2010.00978.x. Review.

11.

A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.

Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, Kahn M, Phan T, Orme IM, Vedvick TS, Baldwin SL, Coler RN, Reed SG.

Sci Transl Med. 2010 Oct 13;2(53):53ra74. doi: 10.1126/scitranslmed.3001094.

12.

Aberrant TGF-beta signaling reduces T regulatory cells in ICAM-1-deficient mice, increasing the inflammatory response to Mycobacterium tuberculosis.

Windish HP, Lin PL, Mattila JT, Green AM, Onuoha EO, Kane LP, Flynn JL.

J Leukoc Biol. 2009 Sep;86(3):713-25. doi: 10.1189/jlb.1208740. Epub 2009 May 19. Erratum in: J Leukoc Biol. 2014 Sep;96(3):503-504. J Leukoc Biol. 2014 Sep;96(3):503-4.

Supplemental Content

Loading ...
Support Center